CA2979853C - Deuterated analogs of etifoxine, their derivatives and uses therof - Google Patents

Deuterated analogs of etifoxine, their derivatives and uses therof Download PDF

Info

Publication number
CA2979853C
CA2979853C CA2979853A CA2979853A CA2979853C CA 2979853 C CA2979853 C CA 2979853C CA 2979853 A CA2979853 A CA 2979853A CA 2979853 A CA2979853 A CA 2979853A CA 2979853 C CA2979853 C CA 2979853C
Authority
CA
Canada
Prior art keywords
compound
chloro
pharmaceutically acceptable
amine
etifoxine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2979853A
Other languages
English (en)
French (fr)
Other versions
CA2979853A1 (en
Inventor
Olivier Dasse
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gaba Inc
Original Assignee
Gaba Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gaba Inc filed Critical Gaba Inc
Publication of CA2979853A1 publication Critical patent/CA2979853A1/en
Application granted granted Critical
Publication of CA2979853C publication Critical patent/CA2979853C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/18—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CA2979853A 2015-03-20 2016-03-18 Deuterated analogs of etifoxine, their derivatives and uses therof Active CA2979853C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562135979P 2015-03-20 2015-03-20
US62/135,979 2015-03-20
PCT/US2016/023231 WO2016154039A1 (en) 2015-03-20 2016-03-18 Deuterated analogs of etifoxine, their derivatives and uses therof

Publications (2)

Publication Number Publication Date
CA2979853A1 CA2979853A1 (en) 2016-09-29
CA2979853C true CA2979853C (en) 2021-05-11

Family

ID=56977741

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2979853A Active CA2979853C (en) 2015-03-20 2016-03-18 Deuterated analogs of etifoxine, their derivatives and uses therof

Country Status (21)

Country Link
US (4) US10080755B2 (https=)
EP (1) EP3347006B1 (https=)
JP (3) JP6762507B2 (https=)
KR (1) KR102290766B1 (https=)
CN (1) CN107530323B (https=)
AU (2) AU2016235495B2 (https=)
BR (1) BR112017020081B1 (https=)
CA (1) CA2979853C (https=)
DK (1) DK3347006T3 (https=)
ES (1) ES2928396T3 (https=)
HR (1) HRP20221240T1 (https=)
HU (1) HUE060240T2 (https=)
IL (2) IL270627B2 (https=)
LT (1) LT3347006T (https=)
MX (1) MX383647B (https=)
PL (1) PL3347006T3 (https=)
PT (1) PT3347006T (https=)
RS (1) RS63654B1 (https=)
SI (1) SI3347006T1 (https=)
SM (1) SMT202200407T1 (https=)
WO (1) WO2016154039A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3347006B1 (en) * 2015-03-20 2022-07-27 GABA Therapeutics Inc. Deuterated analogs of etifoxine, their derivatives and uses therof
US10420773B2 (en) 2017-09-26 2019-09-24 Ovid Therapeutics Inc. Methods of treating developmental disorders and/or seizure disorders with etifoxine
JP2021519276A (ja) * 2018-03-23 2021-08-10 コンサート ファーマシューティカルズ インコーポレイテッド Ｄ−β−ヒドロキシ酪酸の重水素化類似体およびその使用
AU2019270173A1 (en) * 2018-05-18 2020-12-03 Ovid Therapeutics Inc. Methods of treating attention deficit hyperactivity disorder
CN112125862A (zh) * 2019-06-25 2020-12-25 上海安谱实验科技股份有限公司 一种稳定同位素标记的阿特拉津-d5及其合成方法
WO2021097427A1 (en) 2019-11-15 2021-05-20 Karuna Therapeutics, Inc. Xanomeline derivatives and methods for treating neurological disorders
KR20240050372A (ko) * 2021-09-14 2024-04-18 난징 미노바 파마슈티컬 컴퍼니, 리미티드 수용성 알로프레그나놀론 유도체 및 이의 제조 방법과 용도
WO2023218251A1 (en) * 2022-05-10 2023-11-16 Clearsynth Labs Limied Novel deuterium-enriched nefazodone analogues and method for preparing thereof
EP4608408A2 (en) * 2022-10-24 2025-09-03 GABA Therapeutics Inc. Deuterated analogs of etifoxine and methods of administration without autoinduction of metabolism
WO2025085958A1 (en) * 2023-10-23 2025-05-01 Glomesh Intl Pty Ltd A module for mounting items

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1670772C3 (de) 1966-11-24 1978-04-20 Hoechst Ag, 6000 Frankfurt 4H-3,1-Benzoxazin-Derivate, deren Salze und pharmazeutische Präparate
FR2888748B1 (fr) 2005-07-19 2007-10-12 Biocodex Composes neuroprotecteurs et compositions pharmaceutiques les comprenant
US20080039453A1 (en) * 2006-03-20 2008-02-14 David Putman Enantiomerically pure R-etifoxine, pharmaceutical compositions thereof and methods of their use
US8110569B2 (en) * 2006-03-20 2012-02-07 The Regents Of The University Of California Enantiomerically pure S-etifoxine, pharmaceutical compositions thereof and methods of their use
JP2011001308A (ja) * 2009-06-19 2011-01-06 Research Foundation Itsuu Laboratory 重水素化カルボスチリル化合物
SG10201505236YA (en) * 2010-07-09 2015-08-28 Teva Pharma Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
US20140121407A1 (en) 2011-07-05 2014-05-01 Research Foundation Itsuu Laboratory Deuterated phenylpropionic acid derivative
FR3016881B1 (fr) 2014-01-29 2016-03-04 Biocodex Traitement des degenerescences et des lesions photo-induites de la retine
EP3347006B1 (en) * 2015-03-20 2022-07-27 GABA Therapeutics Inc. Deuterated analogs of etifoxine, their derivatives and uses therof

Also Published As

Publication number Publication date
US20230263805A1 (en) 2023-08-24
CA2979853A1 (en) 2016-09-29
SI3347006T1 (sl) 2022-11-30
CN107530323B (zh) 2021-05-04
ES2928396T3 (es) 2022-11-17
US11672805B2 (en) 2023-06-13
CN107530323A (zh) 2018-01-02
US10736901B2 (en) 2020-08-11
IL254567B (en) 2020-03-31
SMT202200407T1 (it) 2022-11-18
RS63654B1 (sr) 2022-11-30
IL270627A (https=) 2019-12-31
EP3347006A1 (en) 2018-07-18
JP2023009114A (ja) 2023-01-19
IL270627B2 (en) 2023-03-01
MX383647B (es) 2025-03-14
AU2016235495B2 (en) 2020-05-14
AU2016235495A1 (en) 2017-10-05
IL270627B (en) 2022-11-01
BR112017020081A2 (pt) 2018-06-05
BR112017020081B1 (pt) 2021-11-30
JP7376668B2 (ja) 2023-11-08
HUE060240T2 (hu) 2023-02-28
JP2018508592A (ja) 2018-03-29
EP3347006B1 (en) 2022-07-27
JP6762507B2 (ja) 2020-09-30
US12433896B2 (en) 2025-10-07
US20180064717A1 (en) 2018-03-08
AU2020201728A1 (en) 2020-03-26
EP3347006A4 (en) 2019-04-24
JP2021001174A (ja) 2021-01-07
LT3347006T (lt) 2022-10-25
IL254567A0 (en) 2017-11-30
PL3347006T3 (pl) 2022-11-14
WO2016154039A1 (en) 2016-09-29
DK3347006T3 (da) 2022-10-17
KR102290766B1 (ko) 2021-08-19
US20200405726A1 (en) 2020-12-31
PT3347006T (pt) 2022-10-17
HRP20221240T1 (hr) 2022-12-09
MX2017011978A (es) 2018-02-09
US20190015419A1 (en) 2019-01-17
US10080755B2 (en) 2018-09-25
KR20170137085A (ko) 2017-12-12
AU2020201728B2 (en) 2021-12-23

Similar Documents

Publication Publication Date Title
CA2979853C (en) Deuterated analogs of etifoxine, their derivatives and uses therof
CN103842348B (zh) 选择性雄激素受体调节剂
EP2571858B1 (en) Phenylmorpholines and analogues thereof
WO2010121022A1 (en) Monoamine reuptake inhibitors
WO2013026455A1 (en) Permanently positively charged antidepressants
WO2007109289A1 (en) Enantiomerically pure s-etifoxine, pharmaceutical compositions thereof and methods of their use
US20240189316A1 (en) Deuterated analogs of etifoxine and methods of administration without autoinduction of metabolism
US5955471A (en) Tetrahydroisoquinolinealkanol derivatives and pharmaceutical compositions containing same
JP7073272B2 (ja) 神経伝達物質放出剤としてのビニローグフェネチルアミン
CZ419599A3 (cs) Hydrochlorid nebo fumarát 1-{2-[(2R)-(3,4-dichlorfenyl)-4-(3,4,5-trimethoxybenzoyl)-morfolin-2-yl]ethyl}spiro[benzo(c)thoifen-1(3H),4'-piperidin]-(2S)-oxid a prostředek ho obsahující
EP3759098A1 (en) Pyridine-sulfonamide compounds and their use against pain and related conditions
HK1192877A1 (zh) 新的皮质多巴胺能-和nmda-受体介导的谷氨酸能神经传递调节剂
HK1192877B (en) Novel modulators of cortical dopaminergic- and nmda-receptor-mediated glutamatergic neurotransmission

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200930

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250310

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250310